Assessing the Legal and Practical Implications of Copay Accumulator and Maximizer Programs.

Drug manufacturers have relied on coupons to promote access to branded drugs by reducing patients' out-of-pocket costs. Insurers and PBMs, on the other hand, have opposed coupons because they undermine the effectiveness of cost-sharing requirements and benefit designs that incentivize cost-effective drug prescribing and purchasing choices.